Medication-info.com Search Menu

Tissueblue Package Insert

Status:
Prescription (Rx) Facts
Strength:
0.0125 mg/0.5 mL
Drug class:
Active ingredient:

Prescribing information (package insert) - Tissueblue

Indications & Usage

TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM).

Dosage & Administration

TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity.

Dosage forms & Strengths

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a clear, bright blue, single-dose ophthalmic solution supplied in 2.25 mL syringes pre-filled to a volume of 0.5 mL.

Contraindications

None

Warnings and Precautions

Excessive Staining

Excess TissueBlue 0.025% should be removed from the eye immediately after staining.

Use of the Syringe

Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula.

Adverse Reactions

Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts.

Use in specific populations

Pregnancy

Risk Summary

There are no available data on the use of TissueBlue 0.025% in pregnant women to inform a drug associated risk. Systemic absorption of TissueBlue 0.025% in humans is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures. Due to the negligible systemic exposure, it is not expected that maternal use of TissueBlue 0.025% will result in fetal exposure to the drug.

Adequate animal reproduction studies were not conducted with TissueBlue 0.025%.

Lactation

Risk Summary

No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or the effects on milk production. However, breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure of BBG in humans following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.

Pediatric use

The safety and effectiveness of TissueBlue 0.025% in pediatric patients has not been established.

Geriatric use

No overall differences in safety or effectiveness were observed between elderly and younger adult patients.

Description

TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is a sterile solution of BBG (a dye) for intraocular ophthalmic use. Each mL of TissueBlue 0.025% contains BBG 0.25 mg, polyethylene glycol and buffered sodium chloride solution (sodium chloride, dibasic sodium phosphate, monobasic sodium phospage, water for injection). Phosphoric acid and/or sodium hydroxide may also be used for pH adjustment. The pH range of TissueBlue 0.025% Solution is between 7.3 and 7.6.

The drug substance BBG has the chemical name Brilliant Blue G, a molecular weight of 854.02 and has the following chemical structure:

Molecular formula: C 47H 48N 3NaO 7S 2

Clinical Pharmacology

Mechanism of action

Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.

Nonclinical toxicology

Nonclinical toxicology

Studies to evaluate the potential for carcinogenicity or impairment of fertility of TissueBlue 0.025% have not been conducted.

Brilliant Blue G was not mutagenic in the Ames assay, the in vitro mouse lymphoma assay, or the in vivo rat micronucleus assay.

How Supplied/Storage and Handling

TissueBlue (Brilliant Blue G Ophthalmic Solution), 0.025% is supplied as 0.5 mL of Brilliant Blue G Ophthalmic Solution, 0.025% in a sterile, single-dose Luer Lok, 2.25 mL glass syringe, with a grey rubber plunger stopper and tip cap with polypropylene plunger rod in a pre-formed polypropylene blister pouch sealed with a Tyvek® lid.

NDC 68803-722-05 (One 0.5 mL syringe)

NDC 68803-722-25 (Carton of five 0.5 mL syringes)

How Supplied/Storage and Handling

TissueBlue 0.025% should be stored at 15°C to 25°C (59°F to 77°F). Protect from light, frost and moisture.

Manufactured for D.O.R.C., Dutch Ophthalmic Research Center (International) B.V., Zuidland, 3214 VN, The Netherlands

Made in Germany

All trademarks are the property of their respective owners.

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 209569 · View the label on DailyMed

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Tissueblue

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Disclosing Agent
Active ingredient Brilliant blue g 0.0125 mg/0.5 mL
Dosage form Injection, solution
Route Intraocular, Ophthalmic
Marketing status listed in the FDA NDC Directory
Company (applicant) DUTCH OPHTHALMIC
FDA approval NDA 209569New Drug Application (NDA) Approved December 20, 2019
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
0.0125 mg/0.5 mL – 0.5 ml in 1 syringe, glass / 1 in 1 pouch / 10 in 1 carton NDC 68803-722-05

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.